Spirulina for Allergic Rhinitis

Verdict: Weak, unreplicated evidence; not recommended

Spirulina has shown promising relief of allergic-rhinitis symptoms in a few small, mostly dated trials, but the evidence is too thin and unreplicated to recommend it, and no health authority or allergy society endorses this use.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The grade is Weak (Tier C) because the clinical case rests on essentially one adequately designed study. In a 24-week double-blind, placebo-controlled RCT of 150 patients at 2,000 mg/day, spirulina significantly reduced nasal discharge, sneezing, congestion and itching versus placebo (PMID 18343939, P<0.001). It is supported only by a small crossover study that measured a single cytokine (IL-4 fell 32%) rather than symptoms (PMID 15857205), and an 8-week trial of 53 patients that lacked a placebo arm, comparing spirulina against cetirizine (PMID 32773785).

These trials are small, dated, of mixed quality, and have undisclosed funding, and the strongest result has never been independently replicated at scale. Regulators treat spirulina only as a food: the US FDA had no questions on its GRAS status, while EFSA and the WHO/FAO take a neutral stance and flag contamination risk from microcystins and heavy metals rather than endorsing any allergy benefit.

Independent clinical sources are unconvinced. NIH ODS and Cleveland Clinic are cautious, saying it may help but that more human research is needed; Mayo Clinic and Harvard do not address it; and the relevant allergy society does not endorse spirulina for rhinitis. Because spirulina is also immunostimulant, it is inadvisable for people with autoimmune disease or on immunosuppressants. Standard treatments such as intranasal corticosteroids and antihistamines remain far better supported.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.42
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
80%
Broadly consistent
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.25
L2 PubMedPrimary literature
0.45
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.422
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (3)L2 · primary research & systematic reviews

The effects of spirulina on allergic rhinitis
PMID: 18343939 2008 RCT (double-blind) n = 150
Finding: Spirulina consumption significantly improved symptoms and physical findings compared with placebo (P < 0.001), including nasal discharge, sneezing, nasal congestion and itching. Authors concluded spirulina is clinically effective on allergic rhinitis versus placebo.
Effect size: Significant symptom improvement vs placebo, P < 0.001 (no standardized effect size reported in abstract)
View on PubMed
Effects of a Spirulina-based dietary supplement on cytokine production from allergic rhinitis patients
PMID: 15857205 2005 RCT (double-blind)
Finding: At 2000 mg/day, spirulina significantly reduced IL-4 levels by 32% from PHA-stimulated cells; ineffective at modulating Th1 cytokines (IFN-gamma, IL-2). Interpreted as suppression of Th2 differentiation. First human feeding study on spirulina for allergic rhinitis — mechanistic/immunologic outcome, not clinical symptom endpoint.
🟠 Limited quality Effect size: IL-4 reduction 32% at 2000 mg/day
View on PubMed
Clinical comparison of the efficacy of spirulina platensis and cetirizine for treatment of allergic rhinitis
PMID: 32773785 2020 隨機對照試驗 n = 53
Finding: Spirulina group showed significantly greater improvement than cetirizine in rhinorrhea (P=0.021), nasal obstruction (P=0.039) and smell reduction (P=0.030); sleep, work capacity and social activity improved more (P<0.05). IL-1alpha, IL-1beta and IL-4 fell while IL-10 rose. Authors concluded spirulina is more effective than cetirizine.
🟠 Limited quality Effect size: Greater symptom improvement vs cetirizine (P<0.05 across cardinal symptoms)
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
FDA had no questions source↗
L4b EU EFSA
Neutral
L4d TW TFDA / 衛福部
Neutral
食用藻類及其製品應符合「食用藻類衛生標準」之規定。 source↗
L4e WHO
Neutral
A review on culture, production and use of spirulina as food for humans and feeds for domestic animals and fish (FAO Fisheries and Aquaculture Circular No. 1034, 2008). source↗
L5a NIH Office of Dietary Supplements
Cautious
L5c Cleveland Clinic
Cautious
L5e Specialty Society (condition-mapped)
Against
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬3 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-allergic-rhinitis-INT-spirulina-001 繁體中文版 →